The studies included were those that examined the diagnostic effectiveness of PSMA PET/CT (covering [<sup>68</sup>Ga]Ga-PSMA-11 and [<sup>18</sup>F]DCFPyL) compared to [<sup>99m</sup>Tc]Tc-MDP BS in identifying bone metastases among prostate cancer patients. This evidence concerns the gene FOLH1 and prostate cancer.